OBJECTIVE: To assess the effect of @entity219 supplementation on neuro-development and growth of preterm neonates. SETTING: Referral neonatal unit of a teaching hospital. DESIGN: Open-labeled Randomized controlled trial. @entity1 : 100 preterm neonates. INTERVENTION: @entity1 randomized to receive oral @entity219 (study group) or not (controls). MAIN OUTCOME MEASURES: Primary: Neuro-development status at 40 weeks post conceptional age and at 3 month corrected age using Amiel-Tison neurologic assessment. Secondary: anthropometry and serum alkaline phosphatase at 3 months corrected age. RESULTS: At 40 weeks post-conceptional age, greater number of @entity219 supplemented @entity1 demonstrated alertness and attention pattern normal for their age (P=0.02). Higher number of controls showed signs of @entity2146 at 40 week post-conceptional age (P=0.001) and 3 months corrected age (P=0.003). At 3 month corrected age, mean serum alkaline phosphatase level was significantly higher in the study group compared to controls. CONCLUSION: @entity219 supplementation till 3 month corrected age in preterm breastfed @entity1 improves alertness and attention pattern; and decreases signs of hyperexcitability, and proportion with abnormal reflexes.

XXXX Supplementation in Preterm Neonates and Neurological Development, A Randomized Controlled Trial.

@entity1 :: ('9606', 'Species') :: ['infants', 'Participants', 'PARTICIPANTS'] @entity219 :: ('MESH:D015032', 'Chemical') :: ['zinc', 'Zinc'] @entity2146 :: ('MESH:D011595', 'Disease') :: ['hyper-excitability']
@entity219 :: (MESH:D015032,Chemical) :: ['Zinc']
